This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
G1 Therapeutics Dividend
Dividend criteriumcontroles 0/6
G1 Therapeutics does not have a record of paying a dividend.
Belangrijke informatie
n/a
Dividendrendement
n/a
Uitbetalingsratio
| Gemiddelde opbrengst industrie | 1.9% |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | n/a |
| Winst per aandeel | -US$0.85 |
| Dividendrendementsvoorspelling | n/a |
Recente dividendupdates
Geen updates
Recent updates
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise
Jul 26
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
Jun 24Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why
Jun 07Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
May 28G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 04Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Mar 22Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
Feb 27Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Jan 04Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
Jun 08New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
May 08The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
Nov 04G1 Therapeutics: Catalysts Stacking
Oct 20G1 Therapeutics: Building A Franchise
Sep 29Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Aug 04G1 Therapeutics Q2 2022 Earnings Preview
Aug 02G1 Therapeutics: Take Advantage Of The November Data
Jul 22Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Insufficient data to determine if GTHX's dividends per share have been stable in the past.
Groeiend dividend: Insufficient data to determine if GTHX's dividend payments have been increasing.
Dividendrendement versus markt
| G1 Therapeutics Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (GTHX) | n/a |
| Markt onderkant 25% (US) | 1.4% |
| Markt Top 25% (US) | 4.3% |
| Gemiddelde industrie (Biotechs) | 1.9% |
| Analist prognose (GTHX) (tot 3 jaar) | n/a |
Opmerkelijk dividend: Unable to evaluate GTHX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hoog dividend: Unable to evaluate GTHX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Winstuitkering aan aandeelhouders
Verdiendekking: Insufficient data to calculate GTHX's payout ratio to determine if its dividend payments are covered by earnings.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: Unable to calculate sustainability of dividends as GTHX has not reported any payouts.